Clinical Trial Update: Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SH T 586 in combination with Rituximab for low-grade non-Hodgkin lymphoma has completed, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SH T 586

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Low-Grade | Phase 2 | Status: COMPLETED